Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (521-530 of 610) with videos related to

Pageof 61
Sort By:
Cancer|March 26, 2003
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemiaApostolia M Tsimberidou, Hagop M Kantarjian, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemiaFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Journal of Immunological Methods|February 2, 2012
Measurement of antibodies to pneumococcal, meningococcal and haemophilus polysaccharides, and tetanus and diphtheria toxoids using a 19-plexed assayAlison M E Whitelegg, Jane Birtwistle, Alex Richter, et al.
Leukemia|February 7, 2013
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignanciesD J DeAngelo, A Spencer, K N Bhalla, et al.
Nano Letters|May 10, 2016
Imaging of Anomalous Internal Reflections of Hyperbolic Phonon-Polaritons in Hexagonal Boron NitrideAlexander J Giles, Siyuan Dai, Orest J Glembocki, et al.
Cancer|April 5, 2002
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemiaSusan O'Brien, Moshe Talpaz, Jorge Cortes, et al.
Leukemia|August 20, 2024
Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trialCarlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Leukemia & Lymphoma|August 15, 2003
A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial)Francis J Giles, Carole B Miller, David D Hurd, et al.
Leukemia Research|May 26, 2004
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemiaAnne-Marie O'Farrell, Helene A Yuen, Beverly Smolich, et al.
Pageof 61

Showing results (521-530 of 610) with videos related to

Sort By:
Pageof 61
Cancer|March 26, 2003
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemiaApostolia M Tsimberidou, Hagop M Kantarjian, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemiaFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Journal of Immunological Methods|February 2, 2012
Measurement of antibodies to pneumococcal, meningococcal and haemophilus polysaccharides, and tetanus and diphtheria toxoids using a 19-plexed assayAlison M E Whitelegg, Jane Birtwistle, Alex Richter, et al.
Leukemia|February 7, 2013
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignanciesD J DeAngelo, A Spencer, K N Bhalla, et al.
Nano Letters|May 10, 2016
Imaging of Anomalous Internal Reflections of Hyperbolic Phonon-Polaritons in Hexagonal Boron NitrideAlexander J Giles, Siyuan Dai, Orest J Glembocki, et al.
Cancer|April 5, 2002
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemiaSusan O'Brien, Moshe Talpaz, Jorge Cortes, et al.
Leukemia|August 20, 2024
Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trialCarlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Leukemia & Lymphoma|August 15, 2003
A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial)Francis J Giles, Carole B Miller, David D Hurd, et al.
Leukemia Research|May 26, 2004
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemiaAnne-Marie O'Farrell, Helene A Yuen, Beverly Smolich, et al.
Pageof 61